Novo Nordisk A/S: FDA schedules Advisory Committee meeting for insulin degludec and insulin degludec/insulin aspart

Novo Nordisk A/S: FDA schedules Advisory Committee meeting for insulin degludec and insulin degludec/insulin aspart
(18 July 2012)
Read the full announcement in PDF format

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has informed the company that an FDA Advisory Committee meeting is tentatively scheduled to be held on 8 November 2012 to discuss the New Drug Applications (NDA) for the ultra-long-acting insulin degludec and insulin degludec/insulin aspart.

Further information:
Media:  Investors:
Mike Rulis  Kasper Roseeuw Poulsen
Tel: (+45) 3079 3573  Tel: (+45) 4442 4303
[email protected]  [email protected]

Frank Daniel Mersebach
Tel: (+45) 4442 0604
[email protected]

Lars Borup Jacobsen
Tel: (+45) 3075 3479
[email protected]

In North America: 
Ken Inchausti  Jannick Lindegaard
Tel: (+1) 609 514 8316  Tel: (+1) 609 786 4575
[email protected]  [email protected]

Company Announcement No 46 / 2012
 

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.